Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

The Lancet

Volumn 388, Issue 10056, 2016, Pages 2153-2163

  French, Jacqueline A ^a   Lawson, John A ^b   Yapici, Zuhal ^c   Ikeda, Hiroko ^d   Polster, Tilman ^e   Nabbout, Rima ^f   Curatolo, Paolo ^g   de Vries, Petrus J ^h   Dlugos, Dennis J ⁱ   Berkowitz, Noah ^j   Voi, Maurizio ^j   Peyrard, Severine ^k   Pelov, Diana ^j   Franz, David N ^l  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c ISTANBUL UNIVERSITY   (Turkey)

^d SHIZUOKA INSTITUTE OF EPILEPSY AND NEUROLOGICAL DISORDERS   (Japan)

^e EPILEPSY CENTER BETHEL   (Germany)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j NOVARTIS PHARMA AG   (Switzerland)

^k NOVARTIS PHARMA K K   (Japan)

^l CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; EVEROLIMUS; LEVETIRACETAM; MULTIDRUG RESISTANCE PROTEIN; PLACEBO; TOPIRAMATE; VIGABATRIN; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT;

ACNE; ADOLESCENT; ADULT; AGE; AGED; APHTHOUS STOMATITIS; ARTICLE; BODY SURFACE; CAREGIVER; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; EAR INFECTION; EPISTAXIS; FEMALE; FOCAL EPILEPSY; GINGIVA PAIN; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; MOUTH ULCER; MULTICENTER STUDY; NEUTROPENIA; OUTCOME ASSESSMENT; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; RHINORRHEA; STOMATITIS; TONGUE ULCER; TUBEROUS SCLEROSIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING; YOUNG ADULT; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; SEIZURES;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EVEROLIMUS; FEMALE; HUMANS; MALE; MIDDLE AGED; SEIZURES; TUBEROUS SCLEROSIS;

EID: 84994853615     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31419-2     Document Type: Article

References (33)

1. 1 Chu-Shore, CJ, Major, P, Camposano, S, Muzykewicz, D, Thiele, EA, The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 51 (2010), 1236–1241.
2. 2 Curatolo, P, Moavero, R, de Vries, PJ, Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol 14 (2015), 733–745.
3. 3 Curatolo, P, Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatr Neurol 52 (2015), 281–289.
4. 4 Kwan, P, Schachter, SC, Brodie, MJ, Drug-resistant epilepsy. N Engl J Med 365 (2011), 919–926.
5. 5 Wong, M, Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies. Epilepsia 51 (2010), 27–36.
6. 6 Feliciano, DM, Lin, TV, Hartman, NW, et al. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits. Int J Dev Neurosci 31 (2013), 667–678.
7. 7 McMahon, J, Huang, X, Yang, J, et al. Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis. J Neurosci 32 (2012), 15704–15714.
8. 8 Meikle, L, Pollizzi, K, Egnor, A, et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 28 (2008), 5422–5432.
9. 9 Talos, DM, Kwiatkowski, DJ, Cordero, K, Black, PM, Jensen, FE, Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers. Ann Neurol 63 (2008), 454–465.
10. 10 Weston, MC, Chen, H, Swann, JW, Multiple roles for mammalian target of rapamycin signaling in both glutamatergic and GABAergic synaptic transmission. J Neurosci 32 (2012), 11441–11452.
11. 11 Zeng, LH, Xu, L, Gutmann, DH, Wong, M, Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 63 (2008), 444–453.
12. 12 Wong, M, Roper, SN, Genetic animal models of malformations of cortical development and epilepsy. J Neurosci Methods 260 (2016), 73–82.
13. 13 Krueger, DA, Care, MM, Agricola, K, Tudor, C, Mays, M, Franz, DN, Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology 80 (2013), 574–580.
14. 14 Krueger, DA, Care, MM, Holland, K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363 (2010), 1801–1811.
15. 15 Krueger, DA, Wilfong, AA, Holland-Bouley, K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 74 (2013), 679–687.
16. 16 Moavero, R, Coniglio, A, Garaci, F, Curatolo, P, Is mTOR inhibition a systemic treatment for tuberous sclerosis?. Ital J Pediatr, 39, 2013, 57.
17. 17 Cardamone, M, Flanagan, D, Mowat, D, Kennedy, SE, Chopra, M, Lawson, JA, Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J Pediatr 164 (2014), 1195–1200.
18. 18 Bissler, JJ, Kingswood, JC, Radzikowska, E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381 (2013), 817–824.
19. 19 Beach, R, Reading, R, The importance of acknowledging clinical uncertainty in the diagnosis of epilepsy and non-epileptic events. Arch Dis Child 90 (2005), 1219–1222.
20. 20 European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders. July 22, 2010. CHMP/EWP/566/98 Rev.2/Corr. http://wwwemaeuropaeu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070043pdf (accessed July 8, 2016).
21. 21 National Cancer Institute. Common terminology criteria for adverse events, (CTCAE), version 4.03. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf, June 14, 2010 (accessed April 15, 2016).
22. 22 Ben-Menachem, E, Biton, V, Jatuzis, D, Abou-Khalil, B, Doty, P, Rudd, GD, Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48 (2007), 1308–1317.
23. 23 Brodie, MJ, Lerche, H, Gil-Nagel, A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 75 (2010), 1817–1824.
24. 24 French, JA, Krauss, GL, Biton, V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 79 (2012), 589–596.
25. 25 Glauser, T, Kluger, G, Sachdeo, R, Krauss, G, Perdomo, C, Arroyo, S, Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 70 (2008), 1950–1958.
26. 26 French, JA, Krauss, GL, Wechsler, RT, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial. Neurology 85 (2015), 950–957.
27. 27 Perucca, E, French, J, Bialer, M, Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 6 (2007), 793–804.
28. 28 Wiegand, G, May, TW, Ostertag, P, Boor, R, Stephani, U, Franz, DN, Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?. Eur J Paediatr Neurol 17 (2013), 631–638.
29. 29 Franz, DN, Belousova, E, Sparagana, S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381 (2013), 125–132.
30. 30 Budde, K, Zonnenberg, BA, Frost, M, et al. Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis. Br J Clin Pharmacol 81 (2016), 958–970.
31. 31 Krueger D, Wilfong A, Talley C, Agricola K, Franz DN. Everolimus shows sustained efficacy for refractory epilepsy in tuberous sclerosis complex (TSC). American Epilepsy Society; Dec 4–8, 2015; Philadelphia, PA, USA. 1251.
32. 32 Meldrum, BS, Rogawski, MA, Molecular targets for antiepileptic drug development. Neurotherapeutics 4 (2007), 18–61.
33. 33 French, J, di Nicola, S, Arrigo, C, Fast and sustained efficacy of levetiracetam during titration and the first 3 months of treatment in refractory epilepsy. Epilepsia 46 (2005), 1304–1307.